Janux Therapeutics, Inc.
JANX
$16.12
$0.120.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 175.03% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 175.03% | -- | |||
| Cost of Revenue | 15.59% | -15.01% | |||
| Gross Profit | 10.19% | 26.84% | |||
| SG&A Expenses | -1.53% | 2.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.57% | -10.51% | |||
| Operating Income | 7.37% | 19.31% | |||
| Income Before Tax | 9.81% | 23.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.81% | 23.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.81% | 23.74% | |||
| EBIT | 7.37% | 19.31% | |||
| EBITDA | 7.46% | 19.53% | |||
| EPS Basic | 10.19% | 24.39% | |||
| Normalized Basic EPS | 10.21% | 24.37% | |||
| EPS Diluted | 10.19% | 24.39% | |||
| Normalized Diluted EPS | 10.21% | 24.37% | |||
| Average Basic Shares Outstanding | 0.43% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||